Read the latest news about the volunteer-centered clinical research organization of reference to pharmaceutical and biotechnology sponsors for managing central nervous system clinical trials and developing innovative treatments worldwide.
RICHARDSON, Texas, June 25th, 2024 — Pillar Clinical Research, a multi-speciality clinical research site network, has announced the appointment of Zach Mitchell as Chief Commercial Officer. In this new appointment, Mitchell will lead Pillar’s commercial functions and strategy, and continue to execute Pillar’s mission for research to be seen as a care option through community outreach initiatives.
Mitchell joins Pillar with a wealth of experience in the clinical research industry, spanning operations, business development and project management across multiple therapeutic indications and phases. He most recently served as executive director of strategic partnerships for CenExel Clinical Research. Prior, he served as director of business operations for iResearch Atlanta, where his exemplary leadership and direction facilitated a successful acquisition in 2021.
“We are honored to bring Zach onto the leadership team at Pillar,” said Carol Witham, CEO of Pillar. “His value to the company extends far beyond his understanding of the industry— it is his passion for participant care and the importance our work has in making a difference in the lives of others. As we navigate this path of continued growth, the demonstrated talent and leadership brought on by Zach will contribute to Pillar’s legacy of excellence.”
“I am thrilled to join the talented team of industry leaders at Pillar,” said Mitchell. “Pillar’s reputation of excellence has established it as an industry touchstone—a metric I strive to maintain in my role. With our aligned vision and potential, I truly believe the sky’s the limit for Pillar.”
Mitchell’s appointment reaffirms Pillar’s commitment to innovating the clinical research landscape and benefits for all stakeholders. Pillar is dedicated to investing in the communities it serves, as well as the development of its employees, facilitating the creation and growth of tomorrow’s leaders within the industry.
###
About Pillar Clinical Research
Pillar Clinical Research provides expert and experienced conduct of early- and late-phase trials for both inpatient and outpatient clinical studies. Founded in Richardson, Texas in 2008, Pillar sets itself apart through superior research services, exceptional participant care and dedication to the advancement of pharmaceutical development. Pillar is proud of a long history of collaboration with contract research organizations (CROs), industry vendors, and clinical based technology providers. For more information, visit www.pillarcr.com.
11/29/2023
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.
Pillar Clinical Research was instrumental in the conduction of the clinical trials that tested KarXT in that our sites in Bentonville, AR, Chicago, Il, and Richardson, TX were involved.
11/29/2023
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.
Pillar Clinical Research was instrumental in the conduction of the clinical trials that tested KarXT in that our sites in Bentonville, AR, Chicago, Il, and Richardson, TX were involved.
8/4/2023
Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a healthcare provider in certain healthcare facilities.
Pillar Clinical Research was instrumental in the conduction of the clinical trials that tested Zurzavae.
Contact us via email for the fastest response. Send us an email.
DALLAS
CHICAGO
NORTHWEST ARKANSAS
CENTRAL ARKANSAS
Business Hours
Monday – Friday
8:30 a.m. – 5 p.m.
Sign up to receive updates, promotions, and sneak peaks of Swab Test.
